- Published on
Emergency and Acute Medicine - Sick Sinus Syndrome
Sick sinus syndrome (SSS) is a collective term describing dysfunction of the sinoatrial (SA) node, resulting in impaired automaticity and abnormal impulse generation. It is most commonly caused by progressive degenerative fibrosis of the sinus node and typically affects older adults, with a mean age over 65 years. The condition is characterized by intermittent or persistent bradyarrhythmias, often without appropriate escape rhythms, and may include a combination of sinus pauses, SA block, and alternating tachyarrhythmias (tachy–brady syndrome). It may also present with delayed recovery of sinus node activity following cardioversion.
Etiologies can be intrinsic or extrinsic. Intrinsic causes include idiopathic fibrosis (most common), ischemic heart disease affecting the SA node, cardiomyopathy, infiltrative diseases such as amyloidosis, inflammatory conditions, and surgical trauma. Extrinsic causes—while not true SSS—can mimic the condition and include medications (e.g., β-blockers, calcium channel blockers, digoxin, amiodarone), electrolyte abnormalities, hypothyroidism, hypothermia, hypoglycemia, and systemic infections such as sepsis. In pediatric patients, SSS may be associated with congenital heart disease or post-surgical complications.
Clinical presentation varies widely. Some patients are asymptomatic, while others experience symptoms due to cerebral hypoperfusion, such as syncope, presyncope, dizziness, fatigue, or altered mental status. Cardiovascular symptoms may include palpitations, chest pain, dyspnea, and exercise intolerance. Physical findings often reveal bradycardia or alternating bradycardia and tachycardia. In severe cases, patients may present with transient ischemic attacks or stroke.
Diagnosis begins with a 12-lead ECG, which may show sinus bradycardia, sinus pauses, SA block, atrial fibrillation with slow ventricular response, or tachy–brady patterns. However, ECG findings may be intermittent, so Holter monitoring or rhythm strips may be necessary. Laboratory evaluation should include electrolytes, thyroid function tests, cardiac markers, and drug levels when appropriate. Imaging such as chest radiography may assist in identifying underlying causes.
Management depends on symptom severity and hemodynamic stability. In unstable patients with symptomatic bradycardia (e.g., hypotension, altered mental status, chest pain), initial treatment includes atropine. If ineffective, transcutaneous pacing should be initiated, followed by transvenous pacing if needed. In patients with tachy–brady syndrome, unstable tachyarrhythmias require cardioversion, but clinicians must anticipate significant post-conversion bradycardia.
Stable patients should be monitored closely, with correction of reversible causes such as medication effects, electrolyte disturbances, hypoxia, or hypothermia. Use of AV nodal blocking agents (e.g., β-blockers, calcium channel blockers, digoxin) should be approached cautiously, as they may worsen bradycardia.
The definitive treatment for symptomatic SSS is placement of a permanent pacemaker, which provides a baseline heart rate and prevents symptomatic bradyarrhythmias. Patients with concurrent atrial fibrillation may require anticoagulation and additional rate or rhythm control strategies.
Patients with new-onset or symptomatic SSS should be admitted for monitoring and cardiology evaluation. Asymptomatic patients may be managed as outpatients with further rhythm monitoring.
Key pitfalls include missing intermittent arrhythmias on ECG and precipitating severe bradycardia with nodal-blocking medications without pacing backup.
Sick sinus syndrome (SSS) is a collective term describing dysfunction of the sinoatrial (SA) node, resulting in impaired automaticity and abnormal impulse generation. It is most commonly caused by progressive degenerative fibrosis of the sinus node and typically affects older adults, with a mean age over 65 years. The condition is characterized by intermittent or persistent bradyarrhythmias, often without appropriate escape rhythms, and may include a combination of sinus pauses, SA block, and alternating tachyarrhythmias (tachy–brady syndrome). It may also present with delayed recovery of sinus node activity following cardioversion.
Etiologies can be intrinsic or extrinsic. Intrinsic causes include idiopathic fibrosis (most common), ischemic heart disease affecting the SA node, cardiomyopathy, infiltrative diseases such as amyloidosis, inflammatory conditions, and surgical trauma. Extrinsic causes—while not true SSS—can mimic the condition and include medications (e.g., β-blockers, calcium channel blockers, digoxin, amiodarone), electrolyte abnormalities, hypothyroidism, hypothermia, hypoglycemia, and systemic infections such as sepsis. In pediatric patients, SSS may be associated with congenital heart disease or post-surgical complications.
Clinical presentation varies widely. Some patients are asymptomatic, while others experience symptoms due to cerebral hypoperfusion, such as syncope, presyncope, dizziness, fatigue, or altered mental status. Cardiovascular symptoms may include palpitations, chest pain, dyspnea, and exercise intolerance. Physical findings often reveal bradycardia or alternating bradycardia and tachycardia. In severe cases, patients may present with transient ischemic attacks or stroke.
Diagnosis begins with a 12-lead ECG, which may show sinus bradycardia, sinus pauses, SA block, atrial fibrillation with slow ventricular response, or tachy–brady patterns. However, ECG findings may be intermittent, so Holter monitoring or rhythm strips may be necessary. Laboratory evaluation should include electrolytes, thyroid function tests, cardiac markers, and drug levels when appropriate. Imaging such as chest radiography may assist in identifying underlying causes.
Management depends on symptom severity and hemodynamic stability. In unstable patients with symptomatic bradycardia (e.g., hypotension, altered mental status, chest pain), initial treatment includes atropine. If ineffective, transcutaneous pacing should be initiated, followed by transvenous pacing if needed. In patients with tachy–brady syndrome, unstable tachyarrhythmias require cardioversion, but clinicians must anticipate significant post-conversion bradycardia.
Stable patients should be monitored closely, with correction of reversible causes such as medication effects, electrolyte disturbances, hypoxia, or hypothermia. Use of AV nodal blocking agents (e.g., β-blockers, calcium channel blockers, digoxin) should be approached cautiously, as they may worsen bradycardia.
The definitive treatment for symptomatic SSS is placement of a permanent pacemaker, which provides a baseline heart rate and prevents symptomatic bradyarrhythmias. Patients with concurrent atrial fibrillation may require anticoagulation and additional rate or rhythm control strategies.
Patients with new-onset or symptomatic SSS should be admitted for monitoring and cardiology evaluation. Asymptomatic patients may be managed as outpatients with further rhythm monitoring.
Key pitfalls include missing intermittent arrhythmias on ECG and precipitating severe bradycardia with nodal-blocking medications without pacing backup.
0 Comments
